Mizuho Securities Keeps Their Buy Rating on Viewray (VRAY)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Viewray (VRAYResearch Report) today and set a price target of $12. The company’s shares closed yesterday at $8.34.

Yang noted:

“We also forecast 26 new orders in 2019 and we believe there is potential upside to our new order forecast. Investors remain focused on competitive dynamics between Unity machine. We continue to believe ViewRay has superior technology with potential to generate significant value over time.”

According to TipRanks.com, Yang is a 5-star analyst with an average return of 19.2% and a 50.1% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.

Currently, the analyst consensus on Viewray is a Strong Buy with an average price target of $14.35, implying a 72.1% upside from current levels. In a report issued on March 11, B.Riley FBR also maintained a Buy rating on the stock with a $13.75 price target.

See today’s analyst top recommended stocks >>

Based on Viewray’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $32.85 million. In comparison, last year the company had a GAAP net loss of $24.65 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ViewRay, Inc. engages in the research, development, and manufacture of magnetic resonance imaging (MRI) system. Its product includes MRIdian, which supports image-guided radiation therapy, stereotactic radiation therapy, and radiosurgery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.

Leave a Reply

Your email address will not be published. Required fields are marked *